This SolarEdge Analyst Turns Bullish; Here Are Top 2 Upgrades For Wednesday
Wall Street analysts upgraded DTM, SEDG. Check out analyst ratings and price targets on Benzinga.
Read original at benzingaStocks · News reference
Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.26) by 15.38 percent. This is unchanged from the same period last year.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Wall Street analysts upgraded DTM, SEDG. Check out analyst ratings and price targets on Benzinga.
Read original at benzingaTop names on Wall Street have had their outlook changed by analysts, including downgrades and price target cuts. See what they think about EIX.
Read original at benzingaTop Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Consider ACMR stock: analysts' thoughts
Read original at benzingaTop Wall Street analysts changed outlook on top names. See analyst ratings for VTEX, FIS, and more. FIS stock analysis also included.
Read original at benzinga